Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811652 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03811652: Completed Phase 1 study, sponsored by MedImmune.
NCT03811652 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03811652, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.
Primary Outcome
To assess the occurrence of adverse events
Interventions
- DRUG MEDI7247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2019-12-10 |
| Phase | Phase 1 |
What the finished NCT03811652 record still lists
NCT03811652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which MEDI7247 is the first listed.
NCT03811652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03811652 about?
NCT03811652 is a clinical study titled "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors". To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further ...
What is the current status of trial NCT03811652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-12-20. Estimated completion is 2019-12-10.
What interventions are being tested in trial NCT03811652?
The interventions under investigation include: MEDI7247 (DRUG).
Who is sponsoring clinical trial NCT03811652?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03811652's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI